In human cells, the oxidative DNA lesion 8,5′-cyclo-2'-deoxyadenosine (CydA) induces prolonged stalling of RNA polymerase II (Pol II) followed by transcriptional bypass, generating both error-free and mutant transcripts with AMP misincorporated immediately downstream from the lesion. Here, we present biochemical and crystallographic evidence for the mechanism of CydA recognition. Pol II stalling results from impaired loading of the template base (5′) next to CydA into the active site, leading to preferential AMP misincorporation. Such predominant AMP insertion, which also occurs at an abasic site, is unaffected by the identity of the 5′-templating base, indicating that it derives from nontemplated synthesis according to an A rule known for DNA polymerases and recently identified for Pol II bypass of pyrimidine dimers. Subsequent to AMP misincorporation, Pol II encounters a major translocation block that is slowly overcome. Thus, the translocation block combined with the poor extension of the dA.rA mispair reduce transcriptional mutagenesis. Moreover, increasing the active-site flexibility by mutation in the trigger loop, which increases the ability of Pol II to accommodate the bulky lesion, and addition of transacting factor TFIIF facilitate CydA bypass. Thus, blocking lesion entry to the active site, translesion A rule synthesis, and translocation block are common features of transcription across different bulky DNA lesions.
In human cells, the oxidative DNA lesion 8,5′-cyclo-2'-deoxyadenosine (CydA) induces prolonged stalling of RNA polymerase II (Pol II) followed by transcriptional bypass, generating both error-free and mutant transcripts with AMP misincorporated immediately downstream from the lesion. Here, we present biochemical and crystallographic evidence for the mechanism of CydA recognition. Pol II stalling results from impaired loading of the template base (5′) next to CydA into the active site, leading to preferential AMP misincorporation. Such predominant AMP insertion, which also occurs at an abasic site, is unaffected by the identity of the 5′-templating base, indicating that it derives from nontemplated synthesis according to an A rule known for DNA polymerases and recently identified for Pol II bypass of pyrimidine dimers. Subsequent to AMP misincorporation, Pol II encounters a major translocation block that is slowly overcome. Thus, the translocation block combined with the poor extension of the dA.rA mispair reduce transcriptional mutagenesis. Moreover, increasing the active-site flexibility by mutation in the trigger loop, which increases the ability of Pol II to accommodate the bulky lesion, and addition of transacting factor TFIIF facilitate CydA bypass. Thus, blocking lesion entry to the active site, translesion A rule synthesis, and translocation block are common features of transcription across different bulky DNA lesions.
RNA polymerase II | translesion transcription | oxidative DNA damage | transcriptional mutagenesis | transcription factor TFIIF A ccurate and efficient genomic DNA transcription into mRNA is crucial for cell survival under DNA damage caused by UV (ultraviolet) irradiation, oxidative stress, or chemical agents. DNA lesions interfere with replication and transcription and cause mutations that grossly affect gene expression (1) . To maintain genomic integrity, cells have evolved an orchestrated interplay of various DNA repair and DNA damage tolerance mechanisms. DNA damage that causes major helical distortion, such as UVinduced cyclobutane pyrimidine dimers (CPDs) and cisplatin adducts, is primarily removed by the nucleotide excision repair (NER) pathway (2) . Nonbulky and nonhelix-distorting DNA lesions are typically processed by the base excision repair (BER) pathway. Despite ongoing DNA repair, some lesions escape detection and pose a roadblock for both replication and transcription machineries. During replication, the deleterious effects of DNA lesions can be alleviated by translesion synthesis (TLS). During TLS, the high-fidelity replicative DNA polymerases are transiently replaced by specialized low-fidelity translesion DNA polymerases that can accommodate bulky lesions within their more spacious active sites, thus enabling their bypass (3, 4) . RNA polymerase II (Pol II) uses a distinct mechanism to bypass DNA lesions: a conformational flexibility of its active center (the flexible trigger loop domain), allowing accommodation of bulky lesions. During transcriptional TLS (lesion bypass), Pol II switches transiently from a highly processive and accurate transcription mode to a translesion mode characterized by low NTP incorporation efficiency and low fidelity (5, 6).
Bulky DNA lesions, such as CPDs and cisplatin adducts, efficiently stall transcription in vitro (7, 8) . Although early studies of the effects of UV light on transcription using randomly damaged plasmids concluded that these lesions were absolute blocks to transcription, several lines of evidence suggest that Pol II is capable of bypassing CPDs in vivo (9) (10) (11) . Recent studies further revealed the intrinsic ability of Pol II to bypass bulky CPD lesions in vitro and suggested the existence of protein factors or cellular conditions that facilitate CPD bypass in vivo (6) . Structural studies of yeast (y) Pol II stalled at CPD lesions and cisplatin-containing DNA revealed a highly constrained protein structure that prevents the lesions from entering the active site. This restriction results in a special empty conformation of the active site that can bind the next NTP without the presence of its pairing template DNA partner. Consequently, Pol II preferentially catalyzes nontemplated AMP insertion opposite the 3′ T moiety of the excluded CPD (3′ T-CPD) or the 3′ G moiety of the cisplatin (6, 7, 12) . Such nontemplated AMP insertion, known as the A rule, was initially described for replicative DNA polymerases encountering a CPD lesion or a noninstructional abasic (aB) site (13, 14) . Subsequently, Pol II catalyzes slow, template-directed nucleotide incorporation opposite the 5′ moiety of these lesions after their translocation to the active Significance Cyclopurines are bulky oxidative DNA lesions that strongly block RNA polymerase II (Pol II) to interfere with gene transcription and replication in mammalian cells. Cells developed a mechanism enabling slow transcriptional bypass of the cyclopurines. Similar to translesion synthesis by DNA polymerases, lesion bypass by Pol II can be highly mutagenic, leading to transcription errors that are reminiscent of the A rule. We elucidated the mechanism and determined the domain in Pol II responsible for error-free and error-prone lesion bypass. We also identified a positive role of mammalian factor TFIIF in lesion-bypass stimulation. Strikingly, Pol II uses a similar strategy for negotiation with different DNA lesions, such as cyclopurines, pyrimidine dimers, cisplatin, and abasic sites, to reduce the burden of DNA damage on genome stability.
site, which completes the CPD/cisplatin bypass. The hindered forward translocation caused by poor accommodation of the lesions in the active site seemed to be a rate-limiting step in the bypass of both lesions by Pol II (7, 12) . Another monofunctional platinum (II) analog pyriplatin, forming a bulky adduct with guanosine residue (Pt-dG), strongly arrests Pol II elongation (15) . The X-ray structure of the Pt-dG-arrested Pol II revealed that the lesion is accommodated in the active site to direct efficient cognate CMP incorporation followed by a complete translocation block, leading to arrest 5′ of the damage site (5, 15) . This translocation block was derived from a preferred interaction between the Pt-dG moiety and the Pol II active site in the pretranslocated register and a poor fit of the lesion in the active site in the posttranslocated register for next nucleotide extension. Thus, the high barrier to forward translocation seems to be a common theme for Pol II's negotiations with chemically different bulky lesions.
Lesion bypass by Pol II can be accurate, resulting in error-free transcripts, or it can generate different types of mutant RNA transcripts in a process called transcriptional mutagenesis (TM) (16) . Much of the data on TM has focused on nonbulky DNA lesions that are repaired by BER, including 8-oxoguanine, uracil, or aB sites (17) . Transcriptional bypass of bulky CPDs in vivo generates mainly WT RNA transcripts, with the polymerase incorporating AMP residues opposite both T residues of the TT dimer (10) . A recent report showed an unexpected, error-prone transcriptional CPD bypass in vivo by human Pol II, involving GMP misincorporation opposite the 3′ T-CPD followed by cognate AMP incorporation opposite the 5′ T-CPD (18) . Transcriptional CPD bypass in vitro involved nontemplated AMP addition opposite the 3′ T-CPD, resulting in the formation of error-free RNA (6). However, GMP was also efficiently misincorporated opposite the 3′ T-CPD (most likely in a nontemplated manner) but poorly extended under the conditions tested, which may explain the predominance of the error-free pathway (6) . In contrast, implementation of the A rule during bypass of a cisplatin-induced 1,2-dGpdG intrastrand cross-link resulted in TM (12) . Thus, the A rule can be mutagenic or not, depending on whether the corresponding DNA base is a T residue.
8,5′-Cyclopurine deoxynucleotide (CyPn) lesions arise from hydroxyl radical attacks on DNA (19) . CyPn lesions can exist in two diastereomeric forms [5′ (R) or 5′ (S)], and both forms are detectable as endogenous DNA lesions (20) . In contrast to the majority of oxidative DNA lesions, which is repaired by the BER pathway, CyPn lesions are specifically repaired by the NER pathway (9, (21) (22) (23) . Therefore, these helix-distorting damages can be considered endogenous analogs of UV-induced CPD lesions. Importantly, CyPn lesions have been proposed to play a causative role in neurodegeneration in patients with xeroderma pigmentosum who lack the capacity for NER. Similar to CPD and cisplatin lesions, CyPn lesions are strong but not absolute blocks to transcription (9, 10) . However, although the vast majority of transcripts resulting from bypass of CPD lesions in vivo was error-free, bypass of 5′ (S) CydA in vivo also generated transcripts, referred to as 5′ A mutations, containing a cognate uridine opposite the lesion and a noncognate adenine opposite the template dA 5′ of the lesion (10) . A subsequent study confirmed the formation of the 5′ A mutations in a different sequence context during transcription across CydA lesions in vivo (24) .
In this study, we investigated the mechanism of transcription through a 5′ (S) CydA lesion by purified yPol II and mammalian [calf thymus (ct)] Pol II. We showed that Pol II was capable of a slow bypass of the lesion with and without the 5′ A mutation and that the 5′ A mutation resulted from a nontemplated AMP insertion according to the A rule. We also identified the mechanism of the error-free CydA bypass, which includes insertion of a cognate nucleotide 5′ of the lesion followed by preferential extension by Pol II compared with the 5′ A mutation. This finding highlights a biologically important mechanism used by Pol II to reduce the burden of transcriptional roadblocks and TM induced by endogenous DNA lesions.
Results
Cyclopurine Lesion in Template DNA Strand Interferes with Pol II Transcription. To investigate CydA processing during transcription by Saccharomyces cerevisiae (yPol II) or ctPol II in vitro, we carried out a structure-function analysis of ternary elongation complexes (TECs) containing a single positioned CydA lesion in the template DNA strand. We first monitored Pol II's encounter with the lesion using promoter-independent in vitro transcription assays with a CydA-stalled TEC carrying a 9-nt 5′-radiolabeled transcript (Fig. 1A and Fig. S1, TEC9 ). TEC9 was reconstituted with its 3′-RNA end positioned 1 bp upstream from the lesion using the 12-subunit Pol II core enzyme and nucleic acid scaffolds as previously described (6) . TEC9 was then incubated with different subsets of 1 mM NTP substrates followed by analysis of the RNA products by denaturing PAGE (Materials and Methods). After 1-h incubation with a physiological concentration of NTPs, most of the RNA was extended by 2 nt, indicating Pol II's ability to transcribe across the CydA lesion ( Fig. 1 A and B , lanes 2-7: N 10 /N 11 ). A time course of the RNA extension showed that the first incorporation opposite the lesion (N 10 ) was relatively fast, whereas the second (N 11 ) and third (N 12 ) incorporations past the lesion were progressively slower, and the fourth in- corporation (N 13 ) finalized the bypass (Fig. 1A, lanes 2-7) . The accumulation of a low but detectable amount of the runoff product after 20-120 min with NTPs indicated that Pol II was capable of a slow bypass of the lesion ( Fig. 1 A and B, runoff) , which was recently reported for UV-induced CPD lesions (6) and platinum-induced monofunctional Pt-dG lesions (5). Consistent with the previous in vivo and in vitro reports, the presence of a CyPn lesion in the transcribed strand is a strong but not absolute block to both yPol II and mammalian Pol II (9, 10) ( Fig. S2A) . Next, we compared the selectivity of nucleotide incorporation opposite CydA 10 and dA 11 (the residue 5′ of the lesion) positions of the template DNA ( Fig. 1 A, lanes 8-36, and B, lanes . RNA products of a similar length but with different 3′-terminal residues had different mobility in the denaturing gel, allowing for distinction between proper UMP (rU 10 ) incorporation and misincorporations (rC 10 , rG 10, and rA 10 ) opposite the lesion (6). Incubation of CydA-TEC9 with NTP subsets revealed that yPol II and ctPol II preferentially inserted a cognate rU 10 opposite CydA. In the presence of cognate UTP only, extension was limited to a single nucleotide, which was poorly extended to the U 11 product ( Fig. 1 A, lanes 2-14, and B, lanes 2-7 and 16-22). The rU 10 product was partially elongated by 1 nt after a 15-min chase with four NTPs (Fig. 1A , lanes 14 and 15 compared with lanes 3 and 15), and some bypass product was also detected (Fig.  1A , lanes 14 and 15). In the presence of ATP only, Pol II efficiently misincorporated rA 10 opposite CydA, albeit at a 10-fold slower rate than that of the cognate rU 10 ( Fig. 1 A and B) . The longer ATP incubation also yielded the rA 11 product, resulting from misincorporated AMP for UMP 1 bp beyond the lesion ( Fig. 1 A, lanes 16-21 and B, lanes [8] [9] [10] [11] [12] [13] [14] . Although Pol II extended the CydA-rA 10 mismatch with the next noncognate AMP (rA 11 ) more efficiently than the CydA-rU 10 match with the next cognate UMP, the rA 11 product was not further extended on subsequent prolonged chase with four NTPs (Fig. 1A , lanes 21 and 22). In contrast, incorporation of a noncognate rG 10 or rC 10 opposite the lesion occurred at a >10-fold slower rate than rU 10 , and both events completely abolished the bypass on subsequent incubation with four NTPs ( Fig. 1 A and B) . This result indicates that the rU 10 incorporation opposite CydA seems to be crucial for lesion bypass by Pol II. Thus, we conclude that the first step in the bypass involves a cognate UMP insertion opposite CydA followed by AMP (the major fraction) or UMP (the minor fraction) addition 1 bp beyond the lesion. A quantitative analysis ( Fig. 1C) indicated that the efficiency of rU 10 incorporation opposite CydA was >100 times slower (3 × 10 −2 s −1 ) than the typical rate of pyrimidine nucleotide insertions by Escherichia coli and yRNA polymerases on the nondamaged DNA (20-100 s −1 ) (25). However, this rate was significantly faster than the reported rate of UMP insertion opposite an aB DNA site (1.2 × 10 −4 s −1 ). This difference indicated that the UMP addition opposite CydA was at least partially templated, which was also consistent with a substantially slower AMP addition opposite CydA compared with UMP. The rA 10 /rC 10 /rG 10 rates opposite CydA were comparable with the corresponding rates at an aB site ( Fig. 1C and Fig. S2 B and C); therefore, we could not exclude the possibility that these events might derive from nontemplated RNA synthesis by Pol II (6) . Indeed, the more than 20-fold higher rate for rA 10 compared with rG 10 /rC 10 suggested that the A rule might be partially applied opposite CydA ( Fig. 1C and Fig. S2C ). The noncognate rC 10 /rG 10 insertions opposite CydA occurred at rates similar to rU→rC and rU→rG misincorporation on the regular DNA, indicating that both insertions likely occur by a mechanism similar to misincorporation on nondamaged DNA (6, 26) . We also ruled out that UMP insertion could derive from template misalignment subsequent to extrahelical flipping out of CydA and downstream adenosinedirected incorporation by replacing the identity of the downstream templating base (27) (5′ dA→dG in Fig. S2D ). Thus, we concluded that Pol II initiates TLS by inserting a cognate UMP opposite CydA followed by insertion of a noncognate AMP or a cognate UMP 1 nt beyond the lesion. A failure of Pol II to rapidly extend the N 11 product in the presence of four NTPs indicates that bond formation 2 nt beyond the lesion (N 11 →N 12 ) is likely to be the rate-limiting step in the CydA bypass.
Cis-and Trans-Acting Factors Stimulate Pol II TLS Through CydA.
We recently described a catalytically hyperactive Rpb1-E1103G mutation in the largest subunit of yPol II that promotes CPD lesion bypass in vitro and increases yeast cell resistance to UV light (6) . The Rpb1-E1103G mutation increases the bulk transcription rate and decreases fidelity of Pol II on nondamaged DNA templates (25) . Additionally, this mutation promotes an error-free CPD lesion bypass by stimulating cognate AMP incorporation opposite both thymines of a CPD, including the first AMP insertion occurring by the A rule (6) . We, therefore, investigated whether the Rpb1-E1103G mutation similarly affected the in vitro ability of Pol II to transcribe through the CydA lesion by incubating CydA-TEC9 formed with E1103G Pol II with NTPs (Fig. 1D) . Consistently, the Rpb1-E1103G mutant promoted nucleotide incorporation opposite and beyond the CydA lesion, which resulted in a substantial increase in the bypass product ( Fig. 1D and Fig. S3A) . Notably, the mutant Pol II significantly enhanced cognate UMP incorporation opposite both CydA and 5′ dA, whereas its effect on noncognate substrate misincorporation was much more subtle (Fig. S3B) . Thus, the error-prone Rpb1-E1103G mutation promoted error-free CydA bypass by stimulating cognate UMP incorporation opposite CydA and the adjacent 5′ adenosine base, such as previously reported during Pol II (Rpb1-E1103G mutation) interactions with CPD lesions (6) .
Similar to the stimulatory effect of the Rpb1-E1103G mutation on yPol II, transcription initiation/elongation factor TFIIF has been shown to increase the catalytic activity of human Pol II in vitro (28, 29) . This finding made TFIIF a potential candidate to facilitate transcription through oxidative DNA lesions (30) . To test this possibility, we carried out in vitro transcription with CydA-TEC9 and CydA-TEC10U assembled with the 12-subunit core enzyme of ctPol II and purified recombinant human TFIIF with various NTP subsets ( Fig. 1D and Fig. S3C ). Consistently, TFIIF stimulated CydA bypass by ctPol II, leading to a substantial fourfold increase in synthesis of the full-length RNA without affecting Pol II fidelity. TFIIF equally increased the rate of nucleotide incorporation opposite CydA and the subsequent cognate (rU 11 ) and noncognate (rA 11 ) incorporation opposite the 5′ dA 11 (Fig. S3C) . Thus, TFIIF promoted both the mutagenic and nonmutagenic CydA bypass pathways.
Nontemplated AMP Insertion by the A Rule as a Second
Step in the Bypass. Recent studies showed that Pol II transcription through CPDs or cisplatin lesions involved nontemplated RNA synthesis according to the A rule (6, 12) . The A rule reflects a strong preference of DNA polymerase for adenine incorporation opposite noninstructional aB DNA lesions (13, (31) (32) (33) . Interestingly, DNA polymerases that encounter a bulky CPD lesion also catalyze nontemplated AMP addition opposite the first thymine of a CPD (34) . The data from Fig. 1 A and B show that yPol II and ctPol II misincorporate noncognate rA 11 more efficiently than cognate rU 11 1 bp beyond CydA, suggesting that the A rule may be implemented 5′ of the CydA lesion. To test this hypothesis, we compared the selectivity and efficiency of NMP insertion during transcription of the CydAdA 11 or CydAaB 11 template with an aB site replacing the undamaged 5′ dA 11 residue. For this experiment, TEC10U was directly assembled on both templates with the primer containing the 3′ RNA end (rU 10 ) complementary to the CydA lesion followed by incubation with NTPs ( Fig. 2A) . Notably, this replacement did not significantly affect Pol II's strong preference for AMP misincorporation at this position ( Fig. 2A and Fig. S2 B and C) . Incubation of TEC10U with ATP alone or with four NTPs resulted in similar RNA extension efficiencies, primarily by 1 nt (rA 11 ) on both templates ( Fig Fig. S1 ) or CydAaB (scaffold B 5′dA→aB in Fig. S1 ) template. CydAaB template contained an aB site replacing the undamaged adenosine 5′ to the CydA lesion. CydA10TEC10U (5′ dA 11 ) and CydA10aB11TEC10U (5′ aB 11 ) were incubated with 1 mM individual NTP for 120 min or four NTPs for the indicated times. Individual NTP reactions were subsequently chased (lanes marked as C) with four NTPs (1 mM). Lower Right shows RNA products resulting from transcription of four different CydA-containing DNA templates with dA (standard), dG, dC, or dT residues 5′ to the CydA (Table S1 ) and incubated with four NTPs (lanes marked as N) or the next cognate NTP (UTP, CTP, GTP, and ATP) for 120 min. Blue arrowheads indicate RNA products of preferential AMP incorporation showing distinct mobility in the gel. Pol II's strong preference for AMP insertion is unaffected by the identity of the 5′ templating base. On the 5′ dC template, GMP (green arrow) was incorporated more efficiently than AMP (∼2:1 ratio; blue arrowheads). The bottom lane shows the amount of runoff product [runoff (RO) percentage] accumulated after 2 h of incubation with four NTPs. Note a two-to fivefold increase in the bypass efficiency on the 5′ dT template compared with the other templates. On the 5′ dT template, AMP incorporation opposite 5′ dT did not generate a mismatch at the RNA 3′ end, thus facilitating RNA extension with the next cognate NMP and subsequent bypass. (B) Parallel pathways 5′ to the CydA lesion. Graphs present the apparent NTP incorporation rates by the matched (squares) and mismatched (circles) -containing TEC11 (scaffolds C dA.rU and C dA.rA in Fig. S1 ) and TEC12 (scaffolds D dA.rU and D dA.rA in Fig. S1 ) in the presence of four NTPs (white symbols) or the next cognate GTP or CTP, respectively (black symbols). (C) NTP incorporation rates during each step of (Left) CydA error-free and errorprone bypass on 5′ dA standard template. The apparent NTP incorporation rate constants (red) are indicated in 10
, and the fractions of normal and mutant RNA generated are in brackets. Dashed lines refer to regular transcription rates obtained on undamaged DNA template. (Right) The preferred cognate GMP and AMP incorporation as opposed to misincorporation was observed on 5′ dC and 5′ dT templates, respectively. On these templates, the error-free bypass was dominant and derived from a combination of the A rule and the templated synthesis 5′ to the CydA. The roman numerals (I-V) indicate steps in the bypass. [16] [17] [18] [19] . Prolonged incubation of CydA-stalled TEC10U with 1 mM UTP or ATP followed by a chase with four NTPs generated the bypass runoff product with a rate similar to that observed with CydA-stalled TEC9 (Fig. 2A, lane 10 , and SI Text). This result was consistent with the data in Fig. 2 showing that the bond formation with rU 10 opposite CydA occurred faster than the subsequent steps in the bypass. Interestingly, the noncognate NTP (mainly GTP) competes with ATP for incorporation beyond CydA, leading to the reduced rA 11 incorporation rate in the presence of four NTPs compared with ATP only (Fig. 2A, Right) . Despite this competition, we hardly detected any GMP misincorporation in the presence of four NTPs (Fig. 2A, lanes 2-5 and 12-15) . This effect was similar to the ATP/GTP competition previously reported for AMP insertion by Pol II opposite an aB site and CPD lesions in DNA (6) . Importantly, the favored AMP insertion also occurred on the templates carrying 5′ dC, 5′ dG, or 5′ dT residues that replace the 5′ dA underlining the robustness of the A rule in different sequence contexts (Fig. 2A, Right) . However, we noted that the 5′ dA→dC substitution partially suppressed the A rule by promoting insertion of the cognate GMP over the noncognate AMP. The 5′ dC residue appeared to frequently enter the active site for base-pairing with GTP. Thus, on the 5′ dC template, Pol II uses a combination of the nontemplated AMP (∼30%) and templated GMP (∼70%) insertion 5′ from the CydA, whereas on the 5′ dA template, the A rule vastly dominated (∼95%) over the templated UMP incorporation. The CydA moiety and/or CydArU 10 base pair might restrain loading of the next 5′ template base to the active center of Pol II, setting conditions for the preferred nontemplated AMP insertion on the 5′ dA template. These constraints appeared to be partially removed on the 5′ dC template containing the less bulky pyrimidine 5′ to the CydA. Consequently, the 5′ dT and 5′ dC pyrimidines substantially increased the bypass ( Fig. 2A) (five-and approximately twofold, respectively) compared with their purine counterparts, which indicated a substantial contribution to the bypass of the templated transcription 5′ to CydA ( Fig. 2A) (the runoff efficiency).
Impaired Mismatch Extension by Pol II Reduces TM. The results in Fig. 1A indicate that the strongest barrier to Pol II progression emerges 5′ of the CydA lesion in the template DNA strand; AMP misincorporation 5′ of CydA and impaired extension of the resulting dA:rA mismatch may contribute to the barrier (12) . To synchronize the bypass, we used TECs containing a complementary uridine in the penultimate RNA position (CydA-rU 10 base pair) and either complementary uridine (TEC11UU) or noncomplementary adenine (TEC11UA) at the 3′ RNA end (Fig.  2B ). With four NTPs or cognate GTP alone, Pol II extended the matched RNA three to five times faster than the mismatch (Fig.  2B , Left, and Fig. S4A ), indicating that AMP misincorporation 5′ of CydA significantly reduced but did not completely abolish the bypass. Our data also suggest that AMP misincorporation is not required for Pol II stalling per se. However, the impaired extension of the dA:rA mismatch contributes to prolonged Pol II stalling 1 nt beyond the lesion. Importantly, a larger fraction of the matched TEC11 (∼30%) compared with its mismatched counterpart (∼10%) was chased to the runoff with four NTPs, causing a substantial enrichment of the error-free RNA as a bypass product (Fig. 2 B and C, step III) . For both TEC11 variants, a significant fraction of the RNA remained nonextendable, even after 2 h of incubation with four NTPs. This phenomenon derived from lesion-induced, irreversible dissociation of the TEC in the course of lesion bypass (Fig. S4B) .
To facilitate lesion bypass further, we used direct TEC assembly with its 3′ RNA end residing 2 bp downstream from the CydA lesion and carrying either a dA:rU 11 match (TEC12UUG) or a dA:rA 11 mismatch (TEC12UAG) in the penultimate RNA base of the RNA-DNA hybrid. Both complexes contained a correctly paired dC:rG 12 at the RNA 3′ end, with CydA localized to the internal part of the RNA-DNA hybrid (Fig. S1 , scaffolds D dA:rU and D dA.rA ). For the matched TEC12UUG, Pol II escape from the lesion site was completed within an ∼10-min incubation with four NTPs, with a rate at least an order of magnitude faster than the two preceding steps of the CydA bypass (Fig. 2B) but with a much slower rate than transcription of the nondamaged DNA (6) . In contrast, the rate of Pol II escape for the mismatched TEC12UAG was severely reduced by ∼10-fold (Fig. 2 B  and C) and occurred with the rates comparable with those of Pol II dissociation. At this step, the competition between Pol II dissociation and extension of the error-containing RNA most likely resulted in a significant enrichment of the bypass product with the error-free RNA.
Finally, the next cognate rC 13 incorporation into both complexes led to a rapid (<1 min) escape from the lesion after addition of four NTPs. Thus, translocation of the CydA moiety at 3 nt from the 3′-RNA end completely relieved translocation and catalytic inhibition of Pol II, allowing completion of the bypass for both the matched and mismatched TECs. We concluded that, along with the poor 3′ mismatch extension, the subsequent mismatch translocation step to the −1 and −2 positions of the RNA-DNA hybrid significantly limits propagation of the RNA error in the full-length transcript, leading to a significant contribution of error-free RNA to the lesion bypass product (Fig. 2C and Fig. S5 ), consistent with in vivo observations (10) .
CydA Lesion in −1 and −2 Sites Impedes Pol II Translocation on DNA.
Several DNA lesions, including the cisplatin and CPD, interfere with forward translocation of Pol II, leading to catalytic arrest caused by occlusion of the active site with the 3′-RNA end. In addition, prolonged Pol II stalling after forward translocation was shown to result from impaired entry of the CPD or cisplatin lesion into the polymerase active site (6, 12) . To investigate the effect of CydA on Pol II translocation at each step of the bypass, we used digestion of the upstream DNA in stalled TECs with exonuclease III (Exo III) to track 1 bp of movement of a rearend Pol II boundary along the DNA (6, 25) . The location of the Pol II boundary revealed rapidly exchanging pre-and posttranslocated states of the same TEC (Fig. 3A) . Typically, the footprint of the pretranslocated boundary gradually disappears during prolonged incubation with Exo III because of the irreversibility of the DNA degradation process, which gives rise to the 1 bp-shifted posttranslocated boundary over time. Fig. 3B illustrates the time-resolved translocation dynamics of a TEC stalled in front of undamaged A 10 /CydA 10 (TEC9), carrying 3′ U 10 in the RNA opposite CydA 10 (TEC10U) and TEC11UU/ TEC11UA as described above. On the nondamaged DNA, the pretranslocated state of TEC9 and TEC10U was detected after 5 s with Exo III followed by a gradual appearance of the posttranslocated state at the longer incubation times (Fig. 3B, lanes  2, 8, and 14) . CydA did not affect this dynamic, indicating that it had no effect on Pol II translocation in either complex (Fig. 3B,  lanes 6, 12, and 18 ). In contrast, CydA caused complete trapping of TEC11UA stalled 1 bp beyond the lesion in the pretranslocated state (Fig. 3B, lanes 20-24) . This result strongly indicated that slow catalysis/NTP binding was primarily responsible for the low catalytic rate of the second and third steps in the error-free bypass, whereas a strong translocation barrier (possibly combined with the low chemistry rate) was responsible for the slowest third step in the error-prone bypass (Fig. 2C and  Fig. S5) . A translocation block was also detected at the subsequent step of the bypass for TEC12UUG and TEC12UAG carrying the lesion 2 nt upstream from the 3′-RNA end (Fig. 3C) . Interestingly, the lesion hardly affected the Exo III footprint dynamic in the mismatched TEC12UAG, which was already residing in the pretranslocated register, even in the absence of the lesion. Apparently, the strong effects of the −1 mismatch in the RNA-DNA hybrid masked an additional impact of the lesion to Pol II translocation equilibrium. Pol II seemed to tolerate the dA: rA 11 mismatch in the +1 (NTP-binding site) and the −1 (3′-RNA end site) sites, whereas its transfer to the −2 site during forward translocation of TEC12UAG was strongly disfavored. Thus, the −2 site in Pol II is the most restrictive for accommodation of both the CydA moiety and the dA:rA mismatch. Taken together, prolonged transcriptional stalling 1 or 2 nt past the lesion mostly derived from AMP misincorporation 5′ of CydA and impaired mismatch extension rather than from lesioninduced distortion of the Pol II active center. This conclusion is consistent with previous findings from work on the other DNA lesions (6, 7).
Structural Basis for CydA-Induced Pol II Stalling and Nontemplated Incorporation. For additional insight into the mechanism of CydA recognition by Pol II, we used X-ray crystallography with elongation complexes assembled on RNA/DNA scaffolds with a CydA lesion in two different registers of the template DNA strand. TEC1 contained a CydA:rU base pair at the −1 position directly upstream from the +1 position on the template DNA strand to mimic the stage subsequent to cognate UMP incorporation opposite CydA (Fig. 4A) (TEC10U) . In this structure, CydA-TEC adopts the pretranslocated conformation, with the 3′ UMP RNA residue occupying the NTP-binding site and slightly tilted toward the penultimate RNA residue (Fig. 4B) . In the post-or pretranslocated TEC on nondamaged DNA (35) (36) (37) , the template DNA +1 base is properly positioned for hybridization with the incoming NTP next to the bridge helix or 3′ RNA (38) . In sharp contrast, the CydA is stably accommodated above the bridge helix, and the canonical +1 site for the templating DNA base is unoccupied in TEC1 structure (Fig. 4 B and C and Fig. S6 A and B) . We also noticed a small peak of positive density corresponding to CydA near the canonical +1 template DNA position, indicating a transient entry of the lesion to the +1 site to base pair with incoming UTP (Fig. 4D , template preinserted state). This small fraction of preinserted CydA is likely to direct template-dependent UTP incorporation (Fig. 1) . Additionally, molecular modeling of the transient entry to the +1 site revealed that CydA only partially stacks with the upstream template DNA base. The covalent bond between C8 and C5′ restrains the accommodation of the CydA purine base into the template +1 position, causing misalignment of UTP in the +1 site and subsequently, preventing full closure of the trigger loop, which is required for rapid phosphodiester bond formation (Fig. 4E) . As a result, the distance between the incorporated 3′ UMP and CydA in the +1 site is significantly larger (>5 Å) than the one between a regular Watson-Crick dA:rU base pair (Fig. 4E) . The lack of a stable pairing at the RNA's 3′ end likely results in Pol II's failure to rapidly move forward from a pretranslocated state to a catalytically competent posttranslocation state for next round of nucleotide incorporation (for formation of 11UU or 11UA). Instead, the CydA template base rotates toward the bridge helix to adopt an inactive intermediate position, which disables its base-pairing with the 3′ RNA end or an incoming NTP substrate. This view is fully consistent with the substantially decreased rate of cognate UMP incorporation opposite CydA described in Fig. 1C . Importantly, CydA occupies a position almost identical to the 3′ dT residue of a CPD lesion in the recently reported CPD-stalled Pol II TEC structure (Protein Data Bank ID code 4A93) (Fig. 4F) . Thus, Pol II adopts a common translocation intermediate that involves displacement of the adducted nucleotide from the active center when encountering these two chemically distinct DNA lesions.
To provide insight into the second most dominant pathway in CydA bypass, we cocrystallized Pol II with a scaffold containing a CydA:rU base pair at the −2 position and a mismatch dA:rA at the −1 position in the template DNA strand (TEC2) to mimic the stage subsequent to nontemplated AMP incorporation (TEC11UA) opposite the base 5′ of CydA (Fig. 5A) . In contrast to a regular posttranslocated TEC, where the 3′ end of the RNA is base-paired with its complementary template DNA base in the −1 position, the CydA base is slightly tilted toward the bridge helix, which narrows the space for accommodating the nondamaged downstream dA base 5′ of CydA in the templating +1 position (Fig. 5A) . As a result, the 5′ dA template base is positioned above the bridge helix. Crystal structure analysis also allowed us to model upstream RNA (up to 10 nt) and the phosphate group connecting the 3′ rA and the penultimate rA (Fig. 5B, Fig. S6 C and D, and Table S2 ). In addition, we observed weak electron density in the secondary channel that may be responsible for the mismatched 3′ rA base at the 3′ terminus of the RNA, suggesting flexible nature of this residue. A model of the fragmented weak density suggested that the 3′rA was likely in a new frayed position, facing the secondary channel (Fig.  S6E) , which would further hinder forward translocation of Pol II. Consistent with the biochemically determined pretranslocated register conformation of the TEC carrying CydA opposite the penultimate position of the nascent RNA (Fig. 3B ) and kinetic studies of slow lesion bypass, the TEC2 structure represented an inactive translocation intermediate that emerges immediately after the nontemplated AMP insertion downstream from CydA but before forward translocation of Pol II.
Discussion
In human cells, oxidative CydA DNA lesions cause a prolonged stalling of Pol II followed by transcriptional bypass, resulting in the generation of both error-free and mutant transcripts (10) . Here, we provide the first biochemical and crystallographic evidence, to our knowledge, for the mechanism of Pol II stalling and bypass of a CydA lesion using purified yPol II and ctPol II. Fig. 6 summarizes the individual steps in the CydA bypass, with the −2, −1, and, +1 sites corresponding to the penultimate, the 3′-RNA terminus, and the NTP-binding site in the posttranslocated TEC, respectively. Similar to other bulky DNA lesions, the CydA lesion does not impose a barrier to Pol II until it reaches the polymerase active center (Fig. 6, step 1 and Fig.  S5 ). Pol II initiates the CydA bypass by a slow templated UMP (TEC10U) incorporation opposite the lesion, indicating Pol II's ability to accommodate CydA in the +1 site without major effects on translocation, consistent with our Exo III footprinting data (Fig. 6, step 2) . Structural analyses revealed a significant misalignment of CydA in the +1 site, resulting in a substantially slower rate of cognate UMP insertion opposite CydA compared with the corresponding insertion on undamaged DNA (Fig. 6,  step 3a) . After UMP incorporation, the majority of Pol II (TEC1 structure) adopts a conformation in which the CydA template base has moved a half-step backward to an inactive intermediate state and is positioned above the bridge helix, whereas the 3′ end of the RNA still occupies the +1 site, thus preventing a subsequent round of NTP addition (Fig. 6, step 3b) . Importantly, this transient translocation intermediate was recently identified during normal transcription on regular templates (39) . Only a small fraction (Fig. 6, step 3a) slowly undergoes forward translocation, in which the CydA-rU pair moves up to the −1 position. However, tilting of CydA narrows the space for the accommodation of the downstream template base 5′ of CydA, preventing it from flipping into the canonical +1 template position to serve as a template and therefore, setting conditions for nontemplated RNA synthesis by the A rule (Fig. 6, step 4a) .
Consistently, the second step in the CydA bypass predominantly involves a nontemplated AMP insertion 5′ of CydA according to the A rule (13) , causing the formation of a 3′ dArA 11 mismatch (Fig. 2A) . The A rule results from impaired loading of the template dA base 5′ of the lesion in the Pol II active site to properly base pair with the cognate UTP. Instead, the 5′ dA base is stably accommodated on top of the bridge helix (Figs. 5A and 6, step 5a). After the nontemplated AMP addition opposite 5′ dA, Pol II encounters a strong translocation block, leading to a dwelling in the catalytically inactive, pretranslocated state (Figs. 3 and 5A and Fig. S5) , consistent with the low catalytic activity of the lesion-stalled TECs (Fig. 2B and Fig. S4A ). Lesion bypass is completed by a slow release from the block, allowing incorporation of the next cognate NMP (Fig. 6, step 6a) . Strikingly, Pol II stalling at CydA results from an impaired delivery of the template base 5′ of CydA into the active center rather than the bulky lesion itself; AMP misincorporation and impaired extension of the resulting mispair contribute to prolonged Pol II stalling (Fig. 2B ). This finding is fully consistent with in vivo results showing that the CydA bypass involves AMP misincorporation 5′ of the lesion in a substantial fraction of the full-length transcripts (10) .
Alternatively, the second step in the bypass involves templated UMP addition (rU 11 ) 5′ of the CydA lesion, albeit at a >20-fold lower efficiency than the 5′ rA 11 misincorporation (Figs. 2C and 6, step 4b and Fig. S5 ). The ability of Pol II to conduct templated synthesis 5′ of the lesion indicates a transient entry of the corresponding template dA 11 base into the Pol II active site to pair with UTP (Fig. 4D ). This mechanism is further supported by the effect of 5′ dA→dC substitution, which promotes the cognate GMP insertion 5′ from the CydA and partially suppresses the A rule ( Fig. 2 A and C) . This effect of 5′ dC is likely caused by the smaller size of the pyrimidine ring compared with bulky purine, which facilitates its entry into the Pol II active site for basepairing with the cognate GTP. Most importantly, the relatively minor level of rU 11 insertion compared with rA 11 contributes significantly to the bypass efficiency because of impaired extension of the lesion-containing dA:rA 11 mismatch during the third and fourth steps (Fig. 6) . The correctly paired 3′ RNA rU 11 may facilitate forward translocation of Pol II by facilitating accommodation of the paired 3′-RNA end in the −1 site or promoting its transfer from the +1 to the −1 site during translocation (Fig. 2B) . Consequently, the bypass results in a considerable enrichment in error-free RNA (Fig. 2C) , which is in good agreement with the in vivo human cell data showing that a large fraction of the CydA bypass products contain a cognate uridine 5′ of the lesion (10) . By the same mechanism, the lesion bypass efficiency increased by approximately fivefold on the template containing the 5′ dT residue replacing 5′ dA. This substitution introduces a cognate dT-rA base pair 5′ to the CydA, which promotes Pol II translocation and consequently, escape from the lesion (Fig. 2 A and C) .
CPDs, CyPn, and cisplatin represent a class of bulky DNA lesions that strongly interfere with Pol II progression (7, 9, 12) . This work and our previous work revealed that Pol II uses a strikingly similar strategy to bypass these chemically different lesions (6, 7, 12) . This similarity likely reflects major spatial constraints on translocation and catalysis imposed by bulky lesions (7, 12) compared with more compact lesions (40) . Interestingly, these constraints differ for CyPn and dinucleotide DNA lesions depending on their location in the −1 and +1 compartments of the Pol II active center. CydA makes a major impact after loading to the +1 site, after passage to the −1 site, and after cognate UMP insertion opposite the lesion. In contrast, CPD and cisplatin lesions interfere (mainly) two steps earlier at the entry to the +1 site (7, 12) . This difference may indicate that the −1 (for 3′-end binding) and +1 (for NTP binding) sites have different capacities for accommodating these chemically different lesions. Accordingly, Pol II preferentially tolerates DNA Fig. 6 . Error-free and error-prone CydA bypass by Pol II on the CydAdA template. The cartoon shows a configuration of the RNA/DNA strands and incoming NTP in Pol II TEC with the RNA (red), DNA (blue), CydA (yellow), bridge helix (green), cognate (red), and noncognate (cyan) NTP with the phosphate moiety. The dotted box corresponds to the NTP-binding site and the +1 template site of the Pol II active center. Each step in the CydA bypass is numbered and described in Discussion. The intermediates 3a/3b and 5a represent the X-ray structures of TEC1 (Fig. 4) and TEC2 (Fig. 5) , respectively. The efficiency and the mutagenic impact of lesion bypass are different on CydAdC and CydAdT templates compared with the CydAdA template as described in Fig. 2 A and C. lesions at specific positions to minimize their impact to TEC translocation and catalysis. For instance, CydA fits well in the −1/+ 1 sites but not the −2 site (1 bp upstream from the active site). In contrast, because of its larger size, Pol II does not tolerate the CPD in the −1/+1 sites compared with CydA, but Pol II is more tolerant of the CPD in the −2 site and beyond, which causes only a minor disturbance in the RNA-DNA hybrid in the TEC compared with CydA. This notion may explain why CydA interferes with elongation downstream of the lesion as opposed to the CPD, which acts directly at the lesion. Strikingly, to avoid the most prominent clashes, Pol II restricts entry of the template downstream (CydA and cisplatin) or upstream (CPD) from the lesion to the +1 site to generate an extra space for NTP binding and catalysis, which results in implementation of the A rule for both lesions, albeit at different registers. For both lesions, nontemplated AMP insertion is followed by a strong translocation block caused by a barrier to transferring the lesion to the −2 site, but the block is stronger for CydA. Thus, the −2 site or a junction between the −1 and −2 sites seems to be the most restrictive among the other registers in allowing passage of the bulky DNA damages. This property is reminiscent of an 8-oxoguanine lesion, which causes a barrier to Pol II 1-2 bp downstream from the lesion rather than at the lesion (40) .
Although our Exo III footprinting data ( Fig. 3 ) strongly support the translocation block as a major contributor to the slow bypass of the CydA and CPD lesions, slow bond formation with the next NMP after translocation cannot be disregarded as an additional contributor for both lesions. This view is supported by the positive correlation between the increased Pol II catalytic activity of the Rpb1-E1103G mutant and the efficiency of the CPD/CydA bypass (6) .
Finally, Pol II uses a remarkably similar strategy to reduce the translocation block at the CydA and CPD lesion by inserting a cognate 3′ NMP at the template position immediately preceding the translocation block. Indeed, any misincorporation at this position significantly inhibits CPD and completely abrogates the CydA bypass (6) (Fig. 1) . This inhibition is explained by additional constraints introduced by the 3′-RNA mismatch to forward translocation and subsequent catalysis. This erroravoidance mechanism may have far-reaching biological implications by reducing TM in living cells because of unrepaired UV and oxidative DNA damages.
Taken together, the A rule seems to be a common strategy for transcription across bulky DNA lesions arising from impaired delivery of the lesion to the Pol II active center. However, the mutagenic consequences of the A rule differ depending on the lesion. TLS by the A rule limits TM at a TT dimer (6) , which is the most common form of CPD generated by UV light (41) . In contrast, the A rule results in mutagenic bypass of cisplatindamaged DNA (12) . Implementation of the A rule during transcription across CydA leads to TM, except at DNA sequences containing a thymine 5′ of the lesion. Strikingly, bypass of chemically diverse CPD, cisplatin, and CyPn lesions reveals recurring themes in their processing by Pol II, including (i) an impaired entry of the lesion into the active center, resulting in nontemplated AMP incorporation by the A rule; (ii) accommodation of the lesion site (for CPD) or the DNA base 5′ of the lesion (for CydA) above the bridge helix, which provides an extra space in the active center for NTP binding and slow catalysis (specifically, in this state, CydA and the 3′ T of the TT dimer occupy a similar position away from the active center to minimize their negative effect on catalysis); and (iii) the intrinsic ability of Pol II to bypass the bulky lesions in vivo.
Pol II stalling and TM at DNA lesions have been proposed to contribute to the initiation and progression of human diseases (6, 42, 43) . Error-free CydA bypass guarantees production of functional proteins in the cell under sustained oxidative DNA damage, whereas the error-prone (A rule) pathway minimizes collisions of the lesion-stalled Pol II with replicative DNA polymerases but at an expense of TM. Consequently, drug molecules that facilitate TFIIF function or mimic the effect of Pol II mutations to facilitate lesion bypass could have therapeutic implications in xeroderma pigmentosum or other neurodegenerative diseases resulting from transcription-blocking DNA lesions.
